心脏缺血/再灌注损伤中心磷脂改变和线粒体功能障碍

Q Medicine

Clinical Lipidology Pub Date : 2015-10-01 DOI:10.2217/clp.15.31

G. Paradies, V. Paradies, F. M. Ruggiero, G. Petrosillo

{"title":"心脏缺血/再灌注损伤中心磷脂改变和线粒体功能障碍","authors":"G. Paradies, V. Paradies, F. M. Ruggiero, G. Petrosillo","doi":"10.2217/clp.15.31","DOIUrl":null,"url":null,"abstract":"Abstract Mitochondrial dysfunction is centrally involved in heart ischemia/reperfusion (I/R) injury. Increased reactive oxygen species production, impaired respiratory chain complexes activity and opening of the mitochondrial permeability transition pore have been suggested as possible factors responsible for mitochondrial dysfunction in heart I/R injury. Cardiolipin (CL), a phospholipid of the inner mitochondrial membrane, plays an important role in mitochondrial bioenergetics. CL alterations have been shown to play a causative role in mitochondrial dysfunction in a variety of pathological conditions, as well as in cell death. The role of CL alterations in mitochondrial dysfunction in heart I/R injury is here reviewed. Several cardioprotective strategies to prevent myocardial injury during I/R targeting mitochondrial CL are also examined.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"13 1","pages":"415 - 429"},"PeriodicalIF":0.0000,"publicationDate":"2015-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"16","resultStr":"{\"title\":\"Cardiolipin alterations and mitochondrial dysfunction in heart ischemia/reperfusion injury\",\"authors\":\"G. Paradies, V. Paradies, F. M. Ruggiero, G. Petrosillo\",\"doi\":\"10.2217/clp.15.31\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Mitochondrial dysfunction is centrally involved in heart ischemia/reperfusion (I/R) injury. Increased reactive oxygen species production, impaired respiratory chain complexes activity and opening of the mitochondrial permeability transition pore have been suggested as possible factors responsible for mitochondrial dysfunction in heart I/R injury. Cardiolipin (CL), a phospholipid of the inner mitochondrial membrane, plays an important role in mitochondrial bioenergetics. CL alterations have been shown to play a causative role in mitochondrial dysfunction in a variety of pathological conditions, as well as in cell death. The role of CL alterations in mitochondrial dysfunction in heart I/R injury is here reviewed. Several cardioprotective strategies to prevent myocardial injury during I/R targeting mitochondrial CL are also examined.\",\"PeriodicalId\":55252,\"journal\":{\"name\":\"Clinical Lipidology\",\"volume\":\"13 1\",\"pages\":\"415 - 429\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"16\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Lipidology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/clp.15.31\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lipidology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/clp.15.31","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 16

摘要

线粒体功能障碍是心脏缺血/再灌注(I/R)损伤的核心机制。活性氧产生增加、呼吸链复合物活性受损和线粒体通透性过渡孔开放被认为是导致心脏I/R损伤中线粒体功能障碍的可能因素。心磷脂(Cardiolipin, CL)是线粒体内膜磷脂，在线粒体生物能量学中起着重要作用。CL改变已被证明在各种病理条件下的线粒体功能障碍以及细胞死亡中起致病作用。本文综述了心肌I/R损伤中CL改变在线粒体功能障碍中的作用。几种心脏保护策略，以防止心肌损伤在I/R针对线粒体CL也进行了研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Cardiolipin alterations and mitochondrial dysfunction in heart ischemia/reperfusion injury

Abstract Mitochondrial dysfunction is centrally involved in heart ischemia/reperfusion (I/R) injury. Increased reactive oxygen species production, impaired respiratory chain complexes activity and opening of the mitochondrial permeability transition pore have been suggested as possible factors responsible for mitochondrial dysfunction in heart I/R injury. Cardiolipin (CL), a phospholipid of the inner mitochondrial membrane, plays an important role in mitochondrial bioenergetics. CL alterations have been shown to play a causative role in mitochondrial dysfunction in a variety of pathological conditions, as well as in cell death. The role of CL alterations in mitochondrial dysfunction in heart I/R injury is here reviewed. Several cardioprotective strategies to prevent myocardial injury during I/R targeting mitochondrial CL are also examined.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Lipidology 生物-生化与分子生物学

CiteScore

0.44

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.